NRBO NeuroBo Pharmaceuticals
- 3.8100
- -0.1100-2.81%
- 3.9800
- +0.1700+4.46%
NeuroBo Pharmaceuticals News
Goldman Sachs Raises Obesity Drug Market Estimate to $130B
NeuroBo Pharmaceuticals Stock Slides Despite Animal Study Showing Wegvoy, Liver Fibrosis Success
NeuroBo Pharmaceuticals Inc (NASDAQ:NRBO) shares were down more than 6% at last check Wednesday.The Boston-based company announced preclinical data for its novel "G-Protein-Coupled Receptor 119 (GPR11
NeuroBo Says DA-1241, Wegovy Combo Shows Potential in Treating MASH
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersMustang Bio (NASDAQ:MBIO) stock increased by 51.6% to $0.47 during Wednesday's pre-market session. The market value of their outstanding shares is at $5.8 million. NeuroBo Pharmaceuticals (NASD
Express News | NeuroBo Pharmaceuticals Sees Reporting Top-Line Data From Both Parts of Ongoing Phase 2a Clinical Trial in Mash in Q4 of This Year
Express News | NeuroBo Pharmaceuticals' Da-1241 in Combination With Semaglutide Improves Liver Fibrosis and Demonstrates Additive Hepatoprotective Effects in Pre-Clinical Mash Models Compared to Either Treatment, Alone
NeuroBo Pharmaceuticals' DA-1241 in Combination With Semaglutide Improves Liver Fibrosis and Demonstrates Additive Hepatoprotective Effects in Pre-Clinical MASH Models Compared to Either Treatment, Alone
"The data being presented at EASL further strengthen the pre-clinical evidence that DA-1241's activation of GPR119 has therapeutic potential for the reduction of hepatic steatosis, inflammation, fibrosis, and improved glucose control," stated Hyung Heon Kim, President and Chief Executive Officer of NeuroBo. "
Buy Rating Affirmed for NeuroBo Pharmaceuticals on Promising Obesity and MASH Drug Developments
NeuroBo Pharmaceuticals | 10-Q: Quarterly report
Express News | NeuroBo Pharmaceuticals Q1 2024 GAAP EPS $(1.32) Misses $(1.10) Estimate
NeuroBo Sees First Patient to Be Dosed in Multiple Ascending Dose Part 2 of Phase 1 Clinical Trial of DA-1726 in 3Q >NRBO
NeuroBo Sees First Patient to Be Dosed in Multiple Ascending Dose Part 2 of Phase 1 Clinical Trial of DA-1726 in 3Q >NRBO
Express News | NeuroBo Pharmaceuticals Inc - Cash of $16.0 Mln, Expected to Fund Company Into Q4 of 2024
Express News | NeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
NeuroBo Pharmaceuticals 1Q Loss $6.71M >NRBO
NeuroBo Pharmaceuticals 1Q Loss $6.71M >NRBO
Maxim Initiates NeuroBo Pharmaceuticals With Buy Rating, $10 Price Target
Maxim Initiates NeuroBo Pharmaceuticals With Buy Rating, $10 Price Target.
NeuroBo Pharmaceuticals Initiated at Buy by Maxim Group
NeuroBo Pharmaceuticals Initiated at Buy by Maxim Group
NeuroBo Pharmaceuticals Price Target Announced at $10.00/Share by Maxim Group
NeuroBo Pharmaceuticals Price Target Announced at $10.00/Share by Maxim Group
Express News | Maxim Group Initiates Coverage On NeuroBo Pharmaceuticals With Buy Rating, Announces Price Target of $10
NeuroBo Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/08/2024 160.42% Maxim Group → $10 Initiates Coverage On → Buy 12/07/2022 56.25% Ladenburg Thalmann → $6
Express News | NeuroBo Pharmaceuticals Inc : Maxim Group Initiates Coverage With Buy and $10 Target Price
Analysis
Price Target
No Data
